Support line (toll-free) (844) 835-4325 | Events help (608) 828-8852 | Community

Free To Breathe - A Partnership For Lung Cancer Survival

participant Login

News

Featured Clinical Trial of the Week: New Treatment for Patients with ALK or EGFR Tumor Mutations

  • July 10 2013

    Share |
    Featured Clinical Trial of the Week: New Treatment for Patients with ALK or EGFR Tumor Mutations

    In the early stages of this clinical trial testing an experimental ALK inhibitor called AP26113, 12 of 16 patients who had previously received the drug crizotinib (Xalkori®) saw their cancers stabilize or shrink.

    As the study expands, researchers will continue to evaluate the effectiveness of AP26113 in patients whose tumors have an ALK or EGFR mutation. This study will also further examine how effective AP26113 is in treating tumors that have become resistant to EGFR or ALK inhibitors such as crizotinib.

    Eligibility
    Non-small cell lung cancer patients with ALK or EGFR tumor mutations.

    Visit ClinicalTrials.gov for more information on this trial.

    If you’re looking for further information on this and/or other lung cancer clinical trials, please contact our Clinical Trials Matching Service, where trained representatives will match your particular cancer and health issues to clinical trials that are available for you.

    0 comments

Leave a comment

Comment Guidelines

Basic HTML formatting permitted -
<ul>, <li>, <strong>, <em>, <a href>, <blockquote>, <code>

©2017 Free To Breathe | Lung Cancer Research Foundation | Federal Tax ID #14-1935776 | LCRF is a 501(c)(3) public charity.